Abstract: The present application provides compounds and methods for reducing coagulation.

Abstract: The present disclosure provides bioorthogonal linkers and reagents, including trans-cyclooctene (“TCO”)- and tetrazine (“Tz”)-containing compounds. In a general aspect, the present disclosure provides reagents, conjugates, and bioactive molecules containing a trans-cyclooctene (“TCO”) fragment. Examples of TCO fragments include: Formulae (I) and (II).

Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): F-L-Tz or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.

Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.

Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.

Abstract: The present invention relates to novel recombinant autonomous parvovirus vectors, novel recombinant virus particles, and novel gene delivery vehicles that can be used to selectively target heterologous nucleic acid sequences to desired cell types and to selectively express such sequences in such desired cell types. Recombinant autonomous parvovirus gene delivery vehicles are particularly advantageous for transient gene therapy, and are especially well-suited to treat diseases in which there is rapid cell growth, such as cancer. Also included is the use of recombinant vectors of the present invention to produce RNA and protein products in cell culture.